NASDAQ:ANEB Anebulo Pharmaceuticals (ANEB) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free ANEB Stock Alerts $2.76 -0.03 (-1.08%) (As of 09:30 AM ET) Add Compare Share Share Today's Range$2.76▼$2.7650-Day Range$2.40▼$3.0452-Week Range$1.62▼$4.05Volume167 shsAverage Volume5,360 shsMarket Capitalization$70.74 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Anebulo Pharmaceuticals alerts: Email Address Anebulo Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside141.5% Upside$6.67 Price TargetShort InterestHealthy0.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.47) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.12 out of 5 starsMedical Sector765th out of 907 stocksPharmaceutical Preparations Industry359th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingAnebulo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnebulo Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.22% of the float of Anebulo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAnebulo Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Anebulo Pharmaceuticals has recently increased by 6.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnebulo Pharmaceuticals does not currently pay a dividend.Dividend GrowthAnebulo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANEB. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Anebulo Pharmaceuticals this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders85.90% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.40% of the stock of Anebulo Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anebulo Pharmaceuticals are expected to decrease in the coming year, from ($0.47) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anebulo Pharmaceuticals is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anebulo Pharmaceuticals is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnebulo Pharmaceuticals has a P/B Ratio of 6.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB)Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Read More ANEB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANEB Stock News HeadlinesApril 17, 2024 | morningstar.comAnebulo Pharmaceuticals Inc 214April 2, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Acrivon Therapeutics, Inc. (ACRV), Abivax SA Sponsored ADR (ABVX)April 25, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. February 26, 2024 | msn.comMilestone rallies 23% on FDA update for tachycardia drugFebruary 16, 2024 | markets.businessinsider.comAnebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA TrackFebruary 15, 2024 | msn.comNew Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What’s the Latest?February 14, 2024 | msn.comSubstance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication DrugFebruary 13, 2024 | finance.yahoo.comAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent UpdatesApril 25, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. January 20, 2024 | benzinga.comAnebulo Pharmaceuticals Stock (NASDAQ:ANEB) Dividends: History, Yield and DatesJanuary 8, 2024 | finance.yahoo.comAnebulo Pharmaceuticals, Inc. (ANEB)December 17, 2023 | nasdaq.comAnebulo Pharmaceuticals (FRA:214) Price Target Increased by 21.00% to 6.80December 9, 2023 | morningstar.comAnebulo Pharmaceuticals Inc ANEBNovember 21, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP) and Brainsway (BWAY)November 17, 2023 | markets.businessinsider.comBuy Recommendation for Anebulo Pharmaceuticals: Promising Financial Outlook and Potential Breakthrough in Acute Cannabis Intoxication TreatmentNovember 15, 2023 | msn.comAnebulo Pharmaceuticals GAAP EPS of -$0.10 beats by $0.02November 14, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNovember 6, 2023 | finance.yahoo.comHere's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn SituationOctober 19, 2023 | msn.comAre Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?October 11, 2023 | benzinga.comDirector at Anebulo Pharmaceuticals Acquires Company Stock Options Worth 26,097 SharesOctober 6, 2023 | marketwatch.comAnebulo Pharmaceuticals Names Richie Cunningham as CEOOctober 6, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of DirectorsOctober 6, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Announces New CEOSeptember 25, 2023 | msn.comHC Wainwright & Co. Reiterates Anebulo Pharmaceuticals (ANEB) Buy RecommendationSeptember 25, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Anebulo Pharmaceuticals (ANEB)September 23, 2023 | nasdaq.comMaxim Group Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy RecommendationSeptember 22, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)See More Headlines Receive ANEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANEB CUSIPN/A CIK1815974 Webwww.anebulo.com Phone512-598-0931FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$6.67 High Stock Price Target$8.00 Low Stock Price Target$6.00 Potential Upside/Downside+141.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-109.40% Return on Assets-98.40% Debt Debt-to-Equity RatioN/A Current Ratio6.72 Quick Ratio6.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book6.73Miscellaneous Outstanding Shares25,630,000Free Float3,614,000Market Cap$70.74 million OptionableNot Optionable Beta-1.00 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Joseph F. Lawler M.D. (Age 52)Ph.D., Founder & Chairman Comp: $11kDr. Kenneth C. Cundy Ph.D. (Age 65)Chief Scientific Officer Comp: $425.15kMr. Richard Anthony Cunningham (Age 53)CEO & Director Mr. Daniel V. George (Age 54)Principal Accounting Officer, Acting CFO & Secretary Mr. Scott L. AndersonHead of Investor Relations & Public AffairsKey CompetitorsLandos BiopharmaNASDAQ:LABPJourney MedicalNASDAQ:DERMCarisma TherapeuticsNASDAQ:CARMViveon Health AcquisitionNYSE:VHAQAssembly BiosciencesNASDAQ:ASMBView All Competitors ANEB Stock Analysis - Frequently Asked Questions Should I buy or sell Anebulo Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANEB shares. View ANEB analyst ratings or view top-rated stocks. What is Anebulo Pharmaceuticals' stock price target for 2024? 3 brokers have issued 1-year price targets for Anebulo Pharmaceuticals' shares. Their ANEB share price targets range from $6.00 to $8.00. On average, they predict the company's stock price to reach $6.67 in the next year. This suggests a possible upside of 141.5% from the stock's current price. View analysts price targets for ANEB or view top-rated stocks among Wall Street analysts. How have ANEB shares performed in 2024? Anebulo Pharmaceuticals' stock was trading at $2.42 at the beginning of the year. Since then, ANEB stock has increased by 14.0% and is now trading at $2.76. View the best growth stocks for 2024 here. Are investors shorting Anebulo Pharmaceuticals? Anebulo Pharmaceuticals saw a increase in short interest in April. As of April 15th, there was short interest totaling 20,100 shares, an increase of 6.9% from the March 31st total of 18,800 shares. Based on an average trading volume of 5,600 shares, the days-to-cover ratio is presently 3.6 days. Currently, 0.2% of the shares of the stock are short sold. View Anebulo Pharmaceuticals' Short Interest. When is Anebulo Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ANEB earnings forecast. How were Anebulo Pharmaceuticals' earnings last quarter? Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) posted its earnings results on Tuesday, February, 13th. The company reported ($0.11) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.11). When did Anebulo Pharmaceuticals IPO? Anebulo Pharmaceuticals (ANEB) raised $21 million in an initial public offering on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company served as the underwriter for the IPO. How do I buy shares of Anebulo Pharmaceuticals? Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANEB) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmith“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
